Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03555149 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT03555149 is a Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 96 participants.
The verdict
NCT03555149, a Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) that became refractory to first- and second-line standard therapies. Eligible patients will be assigned to one of several treatment arms.
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Regorafenib
- DRUG Isatuximab
- DRUG Imprime PGG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2022-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03555149
The ClinicalTrials.gov registry entry for NCT03555149 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03555149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03555149 about?
NCT03555149 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)". A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) that became refractory to first- and second-li...
What is the current status of trial NCT03555149?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2018-09-27. Estimated completion is 2022-09-26.
What interventions are being tested in trial NCT03555149?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Regorafenib (DRUG), Isatuximab (DRUG), Imprime PGG (DRUG).
Who is sponsoring clinical trial NCT03555149?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.